Japanese pharma giant Astellas is entering the booming field of immuno-oncology, pairing up with Cambridge, MA's Potenza Therapeutics to work on a wide variety of treatments that use the body's .

"At Astellas, immuno-oncology is a Primary Focus of our research and development strategy, and we are working on the development of next-generation cancer immuno-therapy using new modalities/technologies," said Kenji Yasukawa, President and CEO, Astellas."The innovative technology in development at Xyphos fits perfectly in advancing our immuno-oncology strategy to create and deliver value for . This deal closely follows Astellas' $3bn acquisition of gene therapy specialist Audentes Therapeutics last month, and will see the Japanese pharma strengthen its capabilities in developing CAR-T therapies for oncology. .

If you want to be part of this exciting work, you belong at Astellas! "We are delighted to work with Astellas, a premier biopharmaceutical company with substantial expertise in immuno-oncology, on this novel modality," said William J. Newell, Sutro's Chief Executive . In a joint statement after, Astellas Pharma and Sutro Biopharma, which is based in South San Francisco, is a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates, announced a worldwide, strategic collaboration and licensing agreement focused on the discovery and development of novel immunostimulatory antibody-drug conjugates (iADCs) We are committed to turning innovative science into medical solutions that bring value and. 28-06-2022.

Immuno-oncology is one of Astellas' main R&D pillars, and the Sutro deal comes shortly after it agreed a $780 million-plus partnership with GO Therapeutics for antibodies targeting two . "At Astellas, immuno-oncology is a Primary Focus of our research and development strategy, and we are working on the development of next-generation cancer immuno-therapy using new modalities . Astellas Pharma is a pharmaceutical company conducting business in more than 70 countries around the world.

If all goes according to plan, Ganymed's shareholders could pick up an additional 860m in milestones, driving the value of the deal up to .

We are also actively collaborating with the best talent to advance innovative science and technologies. .

We believe that this collaboration will .

.

Immuno-oncology is a key area of Astellas' research and the company has been taking strategic actions to bolster this pipeline. Earlier this month, Astellas entered into a definitive agreement .

Bay Area-based CytomX and Astellas forged a strategic relationship worth up to $1.6 billion to discover and develop novel T-cell engaging bispecific antibodies targeting CD3 and tumor cell surface antigens for the treatment of cancer. We are also actively collaborating with the best talent to advance innovative science and technologies.

Astellas has agreed to pay 422m upfront to buy Ganymed Pharmaceuticals, a German biopharma company specialising in antibody-based cancer drugs.

Japanese pharma major Astellas Pharma today announced a worldwide, strategic collaboration and licensing agreement with USA-based drug developer Sutro Biopharma, focused on the discovery and development of novel . We are looking to further expand and maximize our Immuno-Oncology capabilities through additional partnerships and acquisitions - sourced via our highly-active and well-coordinated external .

"The innovative technology in development at Xyphos fits perfectly in advancing our immuno .

With the acquisition Astellas will gain Xyphos' novel and proprietary ACCEL (Advanced Cellular Control through Engineered Ligands) technology platform, as well as industry-leading immuno-oncology .

"At Astellas, immuno-oncology is a Primary Focus of our research and development strategy, and we are working on the development of next-generation cancer immuno-therapy using new modalities . Dr. Yoshida, appointed as head of Immuno-Oncology as of Oct,1, 2021, joined Astellas in 2015, and has led several in-house drug discovery projects in the field of immune-oncology and alliances with external partners in Japan and overseas such as RIKEN, Xencor, CytomX, and Kalivir Immunotherapeutics.

Additional responsibilities include partnering across research divisions, working collaboratively with other Oncology and Immuno-Oncology experts within .

Japanese pharma company Astellas has inked a deal to buy out US-based biotech Xyphos, to bolster its immuno-oncology pipeline.

We believe that this collaboration will .

Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology | Astellas Pharma .

Naoki Okamura, Chief Strategy Officer, at Astellas commented, "Astellas considers Immuno-Oncology as one of the Primary Focuses of its R&D strategy; our goal is to bring effective drugs to .

Immuno-oncology is a key area of Astellas' research and the company has been taking strategic actions to bolster this pipeline.

The collaboration - financial details of which have not been disclosed - will see the companies develop new and novel mechanisms of action in drugs targeting immune checkpoint pathways, co-stimulatory signals and regulatory T cells. 2018 - Astellas acquires Potenza Therapeutics, Inc., Cambridge MA to build a portfolio of novel immuno-oncology therapies. Purpose: The primary purpose of the Scientist I, Oncology role is to design and carry out experiments in the laboratory to build and support Oncology projects in the early discovery pipeline. Astellas Pharma has signed a new and exclusive R&D deal with biotech firm Potenza Therapeutics in the growing new area of immuno-oncology.

At Astellas, Primary Focus Immuno-oncology is one of the priority investment 2019 - Astellas acquires Xyphos Biosciences, Inc. to add talent and a proprietary therapeutic platform to accelerate next-generation cancer immunotherapy. Astellas has immuno-oncology expertise in drug discovery research, clinical development, translational research and manufacturing, with hubs in the U.S. and at the Tsukuba Research Center in Japan. "At Astellas, immuno-oncology is a Primary Focus of our research and development strategy, and we are working on the development of next-generation cancer immuno-therapy using new modalities .

Individual must be . By activating and enhancing the immune system in new and multiple ways, we can reinvigorate its ability to discover, disarm and destroy more cancers in more patients. .

"The innovative technology in development at Xyphos fits perfectly in advancing our .

.

News - Licensing, Immuno-oncology Astellas inks deal with Sutro Biopharma on immunostimulatory antibody-drug conjugates.

The collaboration - financial details of which have not been disclosed - will see the companies develop new and novel mechanisms of action in drugs targeting immune checkpoint pathways, co-stimulatory signals and regulatory T cells.

. "At Astellas, immuno-oncology is a Primary Focus of our research and development strategy, and we are working on the development of next-generation cancer immuno-therapy using new modalities/technologies," said Kenji Yasukawa, President and CEO, Astellas."The innovative technology in development at Xyphos fits perfectly in advancing our immuno-oncology strategy to create and deliver value for .

Astellas has immuno-oncology expertise in drug discovery research, clinical development, translational research and manufacturing, with hubs in the U.S. and at the Tsukuba Research Center in Japan.

- Collaboration to Accelerate Next-Generation Cancer Treatment - TOKYO and CAMBRIDGE, Mass., June 1, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.,. Dr. Yoshida, appointed as head of Immuno-Oncology as of Oct,1, 2021, joined Astellas in 2015, and has led several in-house drug discovery projects in the field of immune-oncology and alliances with external partners in Japan and overseas such as RIKEN, Xencor, CytomX, and Kalivir Immunotherapeutics. Earlier this month, Astellas entered into a definitive agreement . The collaboration - financial details of which have not been disclosed - will see the companies develop new and novel mechanisms of action in drugs targeting immune checkpoint pathways, co-stimulatory signals and regulatory T cells.

"The innovative technology in development at Xyphos fits perfectly in advancing our . Immuno-Oncology opportunity at their Xyphos site in South San Francisco, CA.

Astellas Pharma is a pharmaceutical company conducting business in more than 70 countries around the world.

Astellas Pharma has signed a new and exclusive R&D deal with biotech firm Potenza Therapeutics in the growing new area of immuno-oncology. Astellas Gene Therapies is developing a pipeline of potentially transformative therapies and building industry-leading manufacturing capabilities. Astellas Oncology is the old guard of the pharma industry when it comes to innovation challenges , an affiliate of Tokyo-based Astellas Pharma Inc As of October 5, 2020, in step with the evolving global landscape, Astellas will no longer provide educational funding directly to individual healthcare professionals (HCPs) to attend congresses and . By activating and enhancing the immune system in new and multiple ways, we can reinvigorate its ability to discover, disarm and destroy more cancers in more patients.

"At Astellas, immuno-oncology is a Primary Focus of our research and development strategy, and we are working on the development of next-generation cancer immuno-therapy using new modalities/technologies," said Kenji Yasukawa, President and CEO, Astellas.

respond to existing immuno-oncology treatments.1 We are passionate about turning 20% into 100%.

Division Head. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Job Description: Astellas buys Ganymed to boost immuno-oncology pipeline.

Naoki Okamura, Chief Strategy Officer at Astellas said, "At Astellas, we have positioned Immuno-Oncology as one of the Primary Focuses of our R&D strategy.

Astellas Pharma has signed a new and exclusive R&D deal with biotech firm Potenza Therapeutics in the growing new area of immuno-oncology. Naoki Okamura, Chief Strategy Officer at Astellas said, "At Astellas, we have positioned Immuno-Oncology as one of the Primary Focuses of our R&D strategy. Additional responsibilities include partnering across research divisions, working collaboratively with other Oncology and Immuno-Oncology experts within the Astellas global drug development team to identify ways to develop novel cancer therapies.

Immuno-Oncology opportunity at their Xyphos site in South San Francisco, CA.

"The innovative technology in development at Xyphos fits perfectly in advancing our immuno .

TOKYO and CAMBRIDGE, Mass., April 21, 2015 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo: 4503) and Potenza Therapeutics, Inc., a biotechnology company developing a portfolio of immuno-oncology . Purpose: The primary purpose of the Scientist I, Oncology role is to design and carry out experiments in the laboratory to build and support Oncology projects in the early discovery pipeline. "At Astellas, immuno-oncology is a Primary Focus of our research and development strategy, and we are working on the development of next-generation cancer immuno-therapy using new modalities . "At Astellas, immuno-oncology is a Primary Focus of our research and development strategy, and we are working on the development of next-generation cancer immuno-therapy using new modalities/technologies," said Kenji Yasukawa, President and CEO, Astellas.

We are committed to turning innovative science into medical solutions that bring value and. - Collaboration to Accelerate Next-Generation Cancer Treatment - TOKYO and CAMBRIDGE, Mass., June 1, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.,.

Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology | Astellas Pharma . TOKYO and SOUTH SAN FRANCISCO, Calif., Dec. 26, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Xyphos .

Division Head. Japanese pharma company Astellas has inked a deal to buy out US-based biotech Xyphos, to bolster its immuno-oncology pipeline.

Job Description:

With the acquisition Astellas will gain Xyphos' novel and proprietary ACCEL (Advanced Cellular Control through Engineered Ligands) technology platform, as well as industry-leading immuno-oncology . Astellas Pharma's (OTCPK:ALPMY) (OTCPK:ALPMF) unit Xyphos Biosciences and GO Therapeutics are collaborating to develop novel immuno-oncology therapies.Astellas said GO is applying new advances in .

This deal closely follows Astellas' $3bn acquisition of gene therapy specialist Audentes Therapeutics last month, and will see the Japanese pharma strengthen its capabilities in developing CAR-T therapies for oncology. "At Astellas, immuno-oncology is a Primary Focus of our research and development strategy, and we are working on the development of next-generation cancer immuno-therapy using new modalities/technologies," said Kenji Yasukawa, President and CEO, Astellas.